双时相99mTc-MIBI SPECT/CT鉴别增强实性肾肿瘤良恶性:147例单中心研究
该单中心研究纳入147例(148个病灶)经组织学证实的实性肾肿瘤患者,行双时相99mTc-MIBI SPECT/CT,测量肿瘤与正常肾实质的早期和延迟相对摄取比值(ERUV、DRUV)。良性肾肿瘤的ERUV和DRUV均显著高于恶性肾肿瘤(均P<0.0001);ERUV cutoff 0.53诊断良性肿瘤的灵敏度100%、特异度94.8%、准确率95.3%,DRUV cutoff 0.50对应为100%、96.3%、96.6%。ERUV与DRUV诊断效能无显著差异(P=0.5),且均显著优于滞留指数(均P<0.0001)。
要点
- 双时相99mTc-MIBI SPECT/CT有助鉴别良性肾嗜酸细胞瘤和乏脂性血管平滑肌脂肪瘤与恶性肾肿瘤。
- ERUV cutoff 0.53诊断良性肾肿瘤灵敏度100%、特异度94.8%、准确率95.3%。
- DRUV cutoff 0.50诊断良性肾肿瘤灵敏度100%、特异度96.3%、准确率96.6%,延迟相准确率倾向更高。
核心结论
- 早期和延迟相99mTc-MIBI SPECT/CT均有助于区分良性肾嗜酸细胞瘤及乏脂性血管平滑肌脂肪瘤与恶性肾肿瘤,延迟相诊断准确率倾向更高。
研究设计与样本
- 单中心研究,共180例患者行双时相99mTc-MIBI SPECT/CT(注射后30分钟和90分钟),最终纳入147例患者共148个经组织学证实的实性肾肿瘤进行分析。
主要发现
- 良性肾肿瘤(4个肾嗜酸细胞瘤和8个乏脂性血管平滑肌脂肪瘤)的ERUV和DRUV均显著高于恶性肾肿瘤(n=136;均P<0.0001)。
- ERUV与DRUV在良恶性鉴别中的诊断效能无统计学显著差异(P=0.5)。
- ERUV和DRUV的诊断效能均显著高于滞留指数(均P<0.0001)。
关键数值与推荐
- ERUV cutoff值0.53诊断良性肾肿瘤的灵敏度100%、特异度94.8%、准确率95.3%。
- DRUV cutoff值0.50诊断良性肾肿瘤的灵敏度100%、特异度96.3%、准确率96.6%。
临床怎么用
- 对增强实性肾肿瘤患者,可考虑行双时相99mTc-MIBI SPECT/CT并测量肿瘤与正常肾实质的相对摄取比值,辅助鉴别良性肾嗜酸细胞瘤和乏脂性血管平滑肌脂肪瘤与恶性肾肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the value of dual-phase Tc-MIBI SPECT/CT in the differential diagnosis between benign and malignant enhancing solid renal tumors. PATIENTS AND METHODS: Totally, 180 patients were imaged with dual-phase Tc-MIBI SPECT/CT, which was performed 30 minutes and 90 minutes after Tc-MIBI administration. Among them, 147 patients with 148 histologically proved solid renal tumors met the selection criteria and were included for the final analysis. Relative quantification was performed by measuring the radioactive uptake ratio of tumor to the normal renal parenchymal background for both early and delayed images. RESULTS: Benign renal tumors (4 renal oncocytomas and 8 lipid-poor angiomyolipomas) demonstrated a significantly higher early relative uptake value (ERUV) and delayed relative uptake value (DRUV) than malignant renal tumors (n = 136; both P < 0.0001). The ERUV cutoff value of 0.53 helped to differentiate benign from malignant renal tumors, with sensitivity of 100%, specificity of 94.8%, and accuracy of 95.3% for the diagnosis of benign renal tumors. The DRUV cutoff value of 0.50 helped to differentiate benign from malignant renal tumors, with sensitivity of 100%, specificity of 96.3%, and accuracy of 96.6% for the diagnosis of benign renal tumors. There was no statistically significant difference between the efficacy of ERUV and DRUV in the differential diagnosis between benign and malignant renal tumors (P = 0.5). The efficacies of ERUV and DRUV were all significantly higher than the retention index (both P < 0.0001). CONCLUSIONS: Both early and delayed phase Tc-MIBI SPECT/CT are helpful for distinguishing benign renal oncocytoma and lipid-poor angiomyolipoma from malignant renal tumors, and the delayed phase imaging tends to show higher diagnostic accuracy.
引用
- Zhu H, Yang B, Dong A, et al. Dual-Phase 99mTc-MIBI SPECT/CT in the Characterization of Enhancing Solid Renal Tumors: A Single-Institution Study of 147 Cases. Clin Nucl Med. 2020. PMID: 32701813. doi:10.1097/RLU.0000000000003212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。